Cargando…
Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor–Based Antiretroviral Treatment
BACKGROUND: Integrase strand transfer inhibitors (InSTIs) are recommended for first-line treatment of persons with human immunodeficiency virus (HIV). We identified risk factors, including baseline minor InSTI resistance mutations, for treatment failure of InSTI-based regimens. METHODS: We studied t...
Autores principales: | Pyngottu, Ashima, Scherrer, Alexandra U, Kouyos, Roger, Huber, Michael, Hirsch, Hans, Perreau, Matthieu, Yerly, Sabine, Calmy, Alexandra, Cavassini, Matthias, Stöckle, Marcel, Furrer, Hansjakob, Vernazza, Pietro, Bernasconi, Enos, Günthard, Huldrych F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492202/ https://www.ncbi.nlm.nih.gov/pubmed/33095848 http://dx.doi.org/10.1093/cid/ciaa1614 |
Ejemplares similares
-
Increases in Condomless Sex in the Swiss HIV Cohort Study
por: Kouyos, Roger D., et al.
Publicado: (2015) -
Minor Protease Inhibitor Mutations at Baseline Do Not Increase the Risk for a Virological Failure in HIV-1 Subtype B Infected Patients
por: Scherrer, Alexandra U., et al.
Publicado: (2012) -
Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017) -
Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
por: Scherrer, Alexandra U., et al.
Publicado: (2013) -
Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
por: Scherrer, Alexandra U., et al.
Publicado: (2012)